ProNGF is a potential diagnostic biomarker for thyroid cancer
The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts o...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2016-05, Vol.7 (19), p.28488-28497 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28497 |
|---|---|
| container_issue | 19 |
| container_start_page | 28488 |
| container_title | Oncotarget |
| container_volume | 7 |
| creator | Faulkner, Sam Roselli, Severine Demont, Yohann Pundavela, Jay Choquet, Genevieve Leissner, Philippe Oldmeadow, Christopher Attia, John Walker, Marjorie M Hondermarck, Hubert |
| description | The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p |
| doi_str_mv | 10.18632/oncotarget.8652 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5053740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1812888829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-fc2658b1dbbd126db6fc321e1f5a5db6d9e10df457d124ddf418ed6c21eef03e3</originalsourceid><addsrcrecordid>eNpVUE1PAjEQbYxGCHL3ZHr0stiP7X4cNDFE0ISoBz033X5AddliW0z491ZBxHeZmcybNy8PgHOMRrgqKLlynXRR-LmOo6pg5Aj0cZ3XGWGMHh_0PTAM4Q0lsLysSH0KeqREZc5K3AfXz949TifQBijgykXdRStaqKyYdy5EK2Fj3VL4d-2hcR7GxcY7q6AUndT-DJwY0QY93NUBeJ3cvYzvs9nT9GF8O8skZXnMjCQFqxqsmkZhUqimMJISrLFhgqVJ1RojZZKjtM5V6nClVSETRRtENR2Am63uat0stZLJpRctX3mbrG24E5b_33R2wefukzPEaJmjJHC5E_DuY61D5EsbpG5b0Wm3DhxXmFQJpE5UtKVK70Lw2uzfYMR_gud_wfPv4NPJxaG9_cFvzPQLcsmDbw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812888829</pqid></control><display><type>article</type><title>ProNGF is a potential diagnostic biomarker for thyroid cancer</title><source>Freely Accessible Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Faulkner, Sam ; Roselli, Severine ; Demont, Yohann ; Pundavela, Jay ; Choquet, Genevieve ; Leissner, Philippe ; Oldmeadow, Christopher ; Attia, John ; Walker, Marjorie M ; Hondermarck, Hubert</creator><creatorcontrib>Faulkner, Sam ; Roselli, Severine ; Demont, Yohann ; Pundavela, Jay ; Choquet, Genevieve ; Leissner, Philippe ; Oldmeadow, Christopher ; Attia, John ; Walker, Marjorie M ; Hondermarck, Hubert</creatorcontrib><description>The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.8652</identifier><identifier>PMID: 27074571</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Adenoma - diagnosis ; Adult ; Aged ; Area Under Curve ; Biomarkers, Tumor - analysis ; Carcinoma - diagnosis ; Female ; Humans ; Male ; Middle Aged ; Nerve Growth Factor - analysis ; Nerve Growth Factor - biosynthesis ; Protein Precursors - analysis ; Protein Precursors - biosynthesis ; Research Paper ; ROC Curve ; Sensitivity and Specificity ; Thyroid Neoplasms - diagnosis</subject><ispartof>Oncotarget, 2016-05, Vol.7 (19), p.28488-28497</ispartof><rights>Copyright: © 2016 Faulkner et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-fc2658b1dbbd126db6fc321e1f5a5db6d9e10df457d124ddf418ed6c21eef03e3</citedby><cites>FETCH-LOGICAL-c354t-fc2658b1dbbd126db6fc321e1f5a5db6d9e10df457d124ddf418ed6c21eef03e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053740/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053740/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27074571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faulkner, Sam</creatorcontrib><creatorcontrib>Roselli, Severine</creatorcontrib><creatorcontrib>Demont, Yohann</creatorcontrib><creatorcontrib>Pundavela, Jay</creatorcontrib><creatorcontrib>Choquet, Genevieve</creatorcontrib><creatorcontrib>Leissner, Philippe</creatorcontrib><creatorcontrib>Oldmeadow, Christopher</creatorcontrib><creatorcontrib>Attia, John</creatorcontrib><creatorcontrib>Walker, Marjorie M</creatorcontrib><creatorcontrib>Hondermarck, Hubert</creatorcontrib><title>ProNGF is a potential diagnostic biomarker for thyroid cancer</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.</description><subject>Adenoma - diagnosis</subject><subject>Adult</subject><subject>Aged</subject><subject>Area Under Curve</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma - diagnosis</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nerve Growth Factor - analysis</subject><subject>Nerve Growth Factor - biosynthesis</subject><subject>Protein Precursors - analysis</subject><subject>Protein Precursors - biosynthesis</subject><subject>Research Paper</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Thyroid Neoplasms - diagnosis</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUE1PAjEQbYxGCHL3ZHr0stiP7X4cNDFE0ISoBz033X5AddliW0z491ZBxHeZmcybNy8PgHOMRrgqKLlynXRR-LmOo6pg5Aj0cZ3XGWGMHh_0PTAM4Q0lsLysSH0KeqREZc5K3AfXz949TifQBijgykXdRStaqKyYdy5EK2Fj3VL4d-2hcR7GxcY7q6AUndT-DJwY0QY93NUBeJ3cvYzvs9nT9GF8O8skZXnMjCQFqxqsmkZhUqimMJISrLFhgqVJ1RojZZKjtM5V6nClVSETRRtENR2Am63uat0stZLJpRctX3mbrG24E5b_33R2wefukzPEaJmjJHC5E_DuY61D5EsbpG5b0Wm3DhxXmFQJpE5UtKVK70Lw2uzfYMR_gud_wfPv4NPJxaG9_cFvzPQLcsmDbw</recordid><startdate>20160510</startdate><enddate>20160510</enddate><creator>Faulkner, Sam</creator><creator>Roselli, Severine</creator><creator>Demont, Yohann</creator><creator>Pundavela, Jay</creator><creator>Choquet, Genevieve</creator><creator>Leissner, Philippe</creator><creator>Oldmeadow, Christopher</creator><creator>Attia, John</creator><creator>Walker, Marjorie M</creator><creator>Hondermarck, Hubert</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160510</creationdate><title>ProNGF is a potential diagnostic biomarker for thyroid cancer</title><author>Faulkner, Sam ; Roselli, Severine ; Demont, Yohann ; Pundavela, Jay ; Choquet, Genevieve ; Leissner, Philippe ; Oldmeadow, Christopher ; Attia, John ; Walker, Marjorie M ; Hondermarck, Hubert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-fc2658b1dbbd126db6fc321e1f5a5db6d9e10df457d124ddf418ed6c21eef03e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenoma - diagnosis</topic><topic>Adult</topic><topic>Aged</topic><topic>Area Under Curve</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma - diagnosis</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nerve Growth Factor - analysis</topic><topic>Nerve Growth Factor - biosynthesis</topic><topic>Protein Precursors - analysis</topic><topic>Protein Precursors - biosynthesis</topic><topic>Research Paper</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Thyroid Neoplasms - diagnosis</topic><toplevel>online_resources</toplevel><creatorcontrib>Faulkner, Sam</creatorcontrib><creatorcontrib>Roselli, Severine</creatorcontrib><creatorcontrib>Demont, Yohann</creatorcontrib><creatorcontrib>Pundavela, Jay</creatorcontrib><creatorcontrib>Choquet, Genevieve</creatorcontrib><creatorcontrib>Leissner, Philippe</creatorcontrib><creatorcontrib>Oldmeadow, Christopher</creatorcontrib><creatorcontrib>Attia, John</creatorcontrib><creatorcontrib>Walker, Marjorie M</creatorcontrib><creatorcontrib>Hondermarck, Hubert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faulkner, Sam</au><au>Roselli, Severine</au><au>Demont, Yohann</au><au>Pundavela, Jay</au><au>Choquet, Genevieve</au><au>Leissner, Philippe</au><au>Oldmeadow, Christopher</au><au>Attia, John</au><au>Walker, Marjorie M</au><au>Hondermarck, Hubert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ProNGF is a potential diagnostic biomarker for thyroid cancer</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-05-10</date><risdate>2016</risdate><volume>7</volume><issue>19</issue><spage>28488</spage><epage>28497</epage><pages>28488-28497</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>27074571</pmid><doi>10.18632/oncotarget.8652</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2016-05, Vol.7 (19), p.28488-28497 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5053740 |
| source | Freely Accessible Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Adenoma - diagnosis Adult Aged Area Under Curve Biomarkers, Tumor - analysis Carcinoma - diagnosis Female Humans Male Middle Aged Nerve Growth Factor - analysis Nerve Growth Factor - biosynthesis Protein Precursors - analysis Protein Precursors - biosynthesis Research Paper ROC Curve Sensitivity and Specificity Thyroid Neoplasms - diagnosis |
| title | ProNGF is a potential diagnostic biomarker for thyroid cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T07%3A37%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ProNGF%20is%20a%20potential%20diagnostic%20biomarker%20for%20thyroid%20cancer&rft.jtitle=Oncotarget&rft.au=Faulkner,%20Sam&rft.date=2016-05-10&rft.volume=7&rft.issue=19&rft.spage=28488&rft.epage=28497&rft.pages=28488-28497&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.8652&rft_dat=%3Cproquest_pubme%3E1812888829%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812888829&rft_id=info:pmid/27074571&rfr_iscdi=true |